Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Niklas J. Mackler"'
Autor:
Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski
Publikováno v:
Blood. 140:4349-4351
Autor:
Sikander Ailawadhi, Kevin R. Kelly, Brian G.M. Durie, David Baer, Peter M. Voorhees, Rachael Sexton, Stephen B. Heitner, Adam D. Cohen, Eric M. Rohren, Muneer H. Abidi, Antje Hoering, Robert Z. Orlowski, Suzanne Lentzsch, Niklas J. Mackler
Publikováno v:
Clin Cancer Res
Purpose: Treatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits. Patients and Methods: We report the Southwest Oncology Group randomized phase II trial (S1304) compar
Autor:
Eric M. Rohren, Peter M. Voorhees, Sikander Ailawadhi, Muneer H. Abidi, Niklas J. Mackler, Adam D. Cohen, Kevin R. Kelly, Antje Hoering, Suzanne Lentzsch, Rachael Sexton, Robert Z. Orlowski, Brian G.M. Durie, David Baer, Stephen B. Heitner
Publikováno v:
Journal of Clinical Oncology. 36:8015-8015
8015Background: Cfz has > 1 FDA approved doses in RRMM. Dose-response correlation is assumed without prospective data to compare efficacy of low-dose (27 mg/m2; LDC) vs high-dose Cfz (56 mg/m2; HDC...
Autor:
Vamsidhar Velcheti, Niklas J. Mackler, Shaker R. Dakhil, David S. Shames, Brian Hunis, Tarek Mekhail, Fadi Hayek, Jeffrey D. Neidhart, Cindy Yun, Sarah M. Paul, Sylvia Hu, Nadeem Ikhlaque, Michaela L. Tsai, Christian Antoine El Khoury, Edward S. Kim, See-Chun Phan, Fabio Volterra, Mark A. Socinski, Joan H. Schiller
Publikováno v:
Journal of Clinical Oncology. 35:TPS9103-TPS9103
TPS9103 Background: The anti–PD-L1 monoclonal antibody atezolizumab inhibits the interaction of PD-L1 with its receptors PD-1 and B7.1, thereby restoring T-cell immunity. In the Phase III OAK study, patients with previously treated advanced NSCLC h
Autor:
David Smith, Maha Hussain, Kathleen W. Beekman, James E. Montie, Daniel P. Petrylak, Cheryl T. Lee, Niklas J. Mackler, Rodney L. Dunn, Ulka N. Vaishampayan, Martin G. Sanda, David I. Quinn, Darien Wood
This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with invasive bladder cancer.Patients in arm I had clinical stage T2 with hydronephrosis or T3 b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8957e92ca3ccea7cbd50d7d7b0844fb5
https://europepmc.org/articles/PMC2716704/
https://europepmc.org/articles/PMC2716704/
Autor:
Bruce G. Redman, David Smith, Rodney L. Dunn, Niklas J. Mackler, Judith Fardig, Kenneth J. Pienta, Kathleen A. Cooney, Karin B. Olson
Publikováno v:
Clinical genitourinary cancer. 5(5)
Purpose The primary objective of this study was to assess the feasibility and efficacy of administering etoposide/estramustine/paclitaxel in hormone-sensitive metastatic prostate cancer responding to hormonal therapy. Patients and Methods Eligible pa
Autor:
Niklas J. Mackler, Judith Fardig, Karin B. Olson, Kenneth J. Pienta, Beth A. Hellerstedt, Kathleen A. Cooney, Rodney L. Dunn, David Smith
Publikováno v:
Cancer. 106(12)
BACKGROUND The primary objective of the current study was to identify the tolerable dose level of oral vinorelbine when given in combination with estramustine to men with hormone-refractory prostate cancer (HRPC). The secondary objectives were to des
Autor:
Niklas J. Mackler, Kenneth J. Pienta
Publikováno v:
Nature clinical practice. Urology. 2(2)
Taxanes have emerged as a potent class of chemotherapeutic agents in many malignancies, with two taxanes now in clinical use. Their mechanism of action against tumor cells is by alteration of microtubule dynamics, which causes cell-cycle arrest durin